Chemomab Therapeutics News

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

TEL AVIV, Israel, May 02, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammat

GlobeNewswireMay 2 07:00 ET

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

TEL AVIV, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with

GlobeNewswireApr 24 07:00 ET

Express News | Chemomab Therapeutics Shares Are Trading Higher After the Company Announced the Publication of a New Study Reinforcing the Clinical Association of Its CCL24 Target With Disease Severity and Mortality in Patients With Systemic Sclerosis

Moomoo 24/7Apr 18 12:59 ET

Express News | Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis

Moomoo 24/7Apr 18 07:11 ET

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

—"Breaking New Ground: Expert Perspectives on Primary Sclerosing Cholangitis" Will Feature Clinical, Academic and Patient Advocacy Leaders Discussing PSC Disease Management and Evolving Views on Clinical Development—

GlobeNewswireApr 2 07:00 ET

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) today reported that the European Patent Office has granted a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation.

GlobeNewswireMar 25 07:06 ET

Express News | Oppenheimer Maintains Perform on Chemomab Therapeuticsto Perform

Moomoo 24/7Mar 8 08:45 ET

Express News | Cemomab Therapeutics Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q4 EPS Results

Moomoo 24/7Mar 7 13:13 ET

Express News | Chemomab Therapeutics Q4 EPS $(0.26) Up From $(0.72) YoY

Moomoo 24/7Mar 7 07:06 ET

Earnings Scheduled For March 7, 2024

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. • Stevanato Gr (NYSE:STVN) is likely to report quarte

BenzingaMar 7 04:49 ET

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

PRNewswireMar 5 07:00 ET

12 Health Care Stocks Moving In Thursday's Pre-Market Session

GainersAgile Therapeutics (NASDAQ:AGRX) stock rose 82.4% to $1.81 during Thursday's pre-market session. The company's market cap stands at $5.3 million. Venus Concept (NASDAQ:VERO) stock rose 72.95% t

BenzingaFeb 22 08:05 ET

12 Health Care Stocks Moving In Tuesday's After-Market Session

GainersMotus GI Hldgs (NASDAQ:MOTS) shares rose 53.3% to $1.0 during Tuesday's after-market session. The company's market cap stands at $1.5 million. Acutus Medical (NASDAQ:AFIB) shares increased by 3

BenzingaFeb 20 16:31 ET

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for...

PR NewswireFeb 14 07:00 ET

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

TEL AVIV, Israel, Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative ther

PR NewswireFeb 5 07:00 ET

Express News | Chemomab Therapeutics Announced Publication Of Proteomic Analyses That Further Demonstrate The Unique Role Of The Soluble Protein CCL24 In Driving Pathologies Associated With The Rare Fibrotic Liver Disease Primary Sclerosing Cholangitis

Moomoo 24/7Jan 30 07:05 ET

Express News | Chemomab Announces Completion Of Patient Enrollment In CM-101 Phase 2 Primary Sclerosing Cholangitis Trial And Moves Up Expected Topline Readout To Midyear 2024

Moomoo 24/7Jan 3 07:01 ET

Roth MKM Reinstates Buy on Chemomab Therapeutics, Maintains $7 Price Target

Roth MKM analyst Dylan Dupuis reinstates Chemomab Therapeutics (NASDAQ:CMMB) with a Buy and maintains $7 price target.

BenzingaDec 19, 2023 09:14 ET

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

PRNewswireNov 16, 2023 07:00 ET

Why Is Liver Disease Focused Chemomab Stock Trading Higher Today?

Chemomab Therapeutics Ltd (NASDAQ:CMMB) shares are trading higher after the FDA granted CM-101 Fast Track designation for adult patients of primary sclerosing cholangitis (PSC), a fibrotic liver disease.

BenzingaNov 15, 2023 08:29 ET